Christopher Pan

Christopher Pan has a diverse work experience in the field of research. Christopher currently works as a Research Scientist at Quanta Therapeutics since February 2023. Prior to this, they were a Postdoctoral Researcher at Duke University from October 2016 to January 2023. During their time at Duke, they focused on targeting the THBD signaling pathway for aging-related diseases and identified it as a crucial driver of aging. Before their postdoctoral position, Christopher worked as a Graduate Teaching Associate at The Ohio State University from September 2011 to September 2016. Christopher'sresearch at Ohio State involved investigating signaling mechanisms for endoglin during angiogenesis and assessing the therapeutic effects of TRC105 antibody. Christopher started their research career as an Undergraduate Research Assistant at Rhodes College from January 2008 to May 2008.

Christopher Pan earned their Bachelor's degree in Biochemistry and Molecular Biology from Rhodes College, where they studied from 2007 to 2011. Christopher later pursued a Doctor of Philosophy (PhD) in Pharmacology at The Ohio State University, completing their studies from 2011 to 2016.